More about
Ulcerative Colitis
News
September 12, 2024
2 min read
Save
Tremfya nabs FDA approval for active ulcerative colitis, chasing competitor Skyrizi
The FDA has approved Johnson & Johnson’s Tremfya, a dual acting interleukin-23 inhibitor, for the treatment of patients with moderately to severely active ulcerative colitis, according to a company release.
News
September 06, 2024
4 min read
Save
PBMs vs. patients: The hidden battle for affordable biosimilars
Biosimilar medications — drugs developed to be very similar, but not identical, to an FDA-approved biologic — were intended to play a vital role in increasing affordable options for patients struggling with a range of chronic conditions.
News
September 03, 2024
2 min read
Save
Filgotinib maintains remission, improves quality of life over 4 years in UC
Long-term filgotinib induced and maintained symptomatic remission and improved health-related quality of life in ulcerative colitis, with no new safety signals reported, according to interim analysis of the SELECTION extension study.
Clinical Guidance
Ulcerative Colitis
Assessment and Treatment
Biologics
Clinical Guidance
Ulcerative Colitis
Assessment and Treatment
Immunomodulators
Clinical Guidance
Ulcerative Colitis
Coordinated Management
Health Maintenance
Clinical Guidance
Ulcerative Colitis
Treatment Guidelines
Guidelines
Clinical Guidance
Ulcerative Colitis
Assessment and Treatment
Other Therapies
Clinical Guidance
Ulcerative Colitis
Assessment and Treatment
Surgery
Clinical Guidance
Ulcerative Colitis
Assessment and Treatment